Home
About
Overview
Sharing Data
ORCID
Help
History (2)
Defective preprogramming does not account for the clinical deficits of Parkinsons Disease
Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma.
See All 2 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Defective preprogramming does not account for the clinical deficits of Parkinsons Disease
Defective preprogramming does not account for the clinical deficits of Parkinsons Disease. Behavioral Brain Sciences. 1996; 19:73-74.
authors with profiles
Aron S Buchman